INTRODUCTION
The number of people with diabetes has increased considerably from 108 million people in 1980 to 422 million in 2014 and is expected to reach 700 million by 2025. 1 Globally, the diabetes prevalence among women increased from 5.0% in 1980 to 7.9%. 1 Notably, the growing global burden of diabetes is occurring predominantly in lowincome or middle-income countries where health systems, ravaged by infectious disease, are ill-equipped to deal with the new costly burden (estimated worldwide annual cost of US$825 1 ). In Africa, there has been a rapid increase in the prevalence of diabetes, and consistent with other regions, 90% of cases are type 2 diabetes mellitus (T2DM). [2] [3] [4] For example, in Tanzania and Cameroon, repeated local surveys using similar methods revealed that T2DM increased by 6-fold and 10-fold in a decade, respectively. 3 5 This increase in prevalence has led to estimates by the International Diabetes Federation (IDF) that the number of people in the region with T2DM is expected to more than double by 2035 relative to 2013. 6 Considerations for the huge human and economic burden that results from treating T2DM and its complications have led to calls by the IDF for the
Strengths and limitations of this study
▪ This research will provide a comprehensive overview of all the data on the prevalence of type 2 diabetes in women of childbearing age in Africa, using repeatable transparent robust systematic review methods. ▪ Age-specific prevalence data may not be available for some studies.
establishment of national diabetes programmes to better deliver prevention and control solutions. 6 At the heart of these efforts is a drive to identify high-risk populations, context specific-risk factors and implementing effective interventions to prevent or delay the onset of T2DM.
Women of childbearing age, defined by the WHO as women aged between 15 and 49 years, 7 are affected by T2DM in a unique way. If a woman has T2DM and becomes pregnant, her unborn child is at high risk of developing T2DM in adulthood, 8 thereby accelerating the intergenerational risk of T2DM. Interventions to prevent and control T2DM in this group is further warranted given the important contribution women make to the social and economic development of nations, the health and well-being of their children and families. Furthermore, women are valuable conduits for introducing healthy lifestyles in their families and communities.
The modifiable risk factors for T2DM are on the rise in all populations. In particular, overweight and obesity, the main drivers of the T2DM epidemic, are increasing worldwide and especially so in women. 9 In Africa, the increase in overweight and obesity is attributed to the nutrition transition and modernisation characterised by adoption of energy dense 'Western' diets and decreased physical activity, 10 although the evidence linking these factors to obesity in Africa is sparse. Other context specific factors such as cultural practices where being overweight is associated with higher economic status 11 12 may also be contributing to overweight and obesity in this group. Obesity is thought to result in T2DM through excess visceral fat deposition that often results in ectopic fat deposition in the liver and other abdominal organs, leading to insulin resistance. 13 Epidemiological studies have demonstrated a strong association with up to 90% of T2DM being attributable to overweight and obesity. 14 Worldwide, the proportion of women who are obese is marginally higher than that of men (40% vs 38%). 14 However, in low-income to middle-income countries, Africa included, more women are obese compared to men. 9 Multiparity may increase a woman's risk of obesity 15 and resultant T2DM, although the evidence is inconsistent. 16 A higher gestational weight has also been, in turn, associated with increased risk of weight gain, and a consequent risk of overweight and obesity after pregnancy. 17 In Africa, the data on weight gain after pregnancy appear to be even scarcer, although women tend to have more children, compared to those in the developed world and therefore go through multiple pregnancy cycles, 18 19 with the associated incremental weight gain after each cycle.
Africa has the greatest global burden of HIV, with women of childbearing age the group most affected. 20 As a consequence of the successful rollout of antiretroviral therapy (ART) in many African countries, a large number of women have access to ART and life expectancy has increased. ART, including the drugs in widespread use in the region, however, has been linked with T2DM risk, 21 which may impact the prevalence of T2DM in women of childbearing age.
The existing studies in Africa have not been previously collated, although there are perceptions that the prevalence of T2DM in women of childbearing age may be on the increase in the continent. This research will provide information on patterns and the distribution of T2DM to policymakers and possibly identify priority areas for intervention. We hope that the identification of risk factors specific to the African women of childbearing age will improve the development of effective interventions to delay or prevent T2DM in the continent.
Aim
The aim of this systematic review is to assess the prevalence of and the risk factors for the development of T2DM in African women aged between 15 and 49 years as reported in studies during the period 2000 to 2016. The lower cut-off of the year 2000 will be used as studies conducted earlier may have used different criteria for the diagnosis of T2DM.
Objectives To achieve the above aim, the research objectives will be: 1. To estimate the prevalence of T2DM in women of childbearing age in Africa, as reported in studies during the years 2000 to 2016. 2. To determine risk factors for T2DM in women of childbearing age in Africa, as reported in research studies conducted during the years 2000 to 2016.
Research question
This systematic review will answer the following question: what is the prevalence of and risk factors for T2DM in women of childbearing age in Africa as reported in studies published during the period 2000 to 2016?
Study design
This protocol is registered online on PROSPERO, the International prospective register of systematic reviews (http:www.crd.york.ac.uk/PROSPERO, registration no. CRD42015027635). The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 22 guidelines for reporting systematic reviews will be followed.
Criteria for considering studies for review Types of studies The systematic review will include cross-sectional studies and any other observational studies that assessed the prevalence of and risk factors for T2DM.
Studies inclusion criteria 1. All published and unpublished cross-sectional and community-based studies during the period 2000 to 2016 are reporting the prevalence of, risk factors for, T2DM in women aged 15-49 years, where the sample of women in this age range was at least 100.
2. Diagnosis of T2DM should have been according to the WHO 1999 guidelines 23 or an equivalent. 3. No language restriction will be applied.
Studies exclusion criteria
Studies will be excluded if: 1. Used criteria not comparable to the WHO 1999 guidelines in diagnosing T2DM. 2. They are duplicate publications. In the case of duplicate publications, only one article that contains the most information will be included in the review. 3. They are narrative review, letters to the editor, opinions or other publications that do not have primary data. 4. Studies in migrant Africans.
Types of outcomes
The prevalence of the following will be assessed from studies included in the systematic review.
Primary outcomes T2DM as diagnosed according to the WHO 1999 guidelines: fasting blood glucose of at least 7.0 mmol/L or 2-hour oral glucose tolerance test (OGTT) blood glucose of 11.1 mmol/L. 23 
Secondary outcomes
Impaired glucose regulation (IGR), which will be defined as either impaired glucose tolerance (fasting blood glucose <7.0 mmol/L and 2-hour OGTT blood glucose of at least 7.8 mmol/L but <11.1 mmol/L) or impaired fasting glucose (fasting blood glucose >6.1 mmol/L but <7.0 mmol/L). 23 
Search strategy for identification of relevant studies Data sources
The following sources will be searched for studies conducted during the period January 2000 to March 2016:
Electronic databases 1. Electronic databases including PubMed-MEDLINE, the Cochrane Central, Global Health, Scopus, CINAHAL, ISI web of science and POPLINE and AfricaWide 2. Grey literature databases such as OpenSigle Hand searching 1. All references of retrieved articles will be scanned for further studies. 2. Prominent authors of articles will be contacted for information on other studies they may know.
Search methods for identification of studies
A comprehensive and sensitive search strategy using an African search filter will be utilised to identify research articles from the year 2000 to 2016 (see online supplementary appendix 1). An expert librarian will be consulted during the design of the search strategy.
Individual African country names and regional grouping names, such as sub-Saharan Africa and North Africa, will also be used to identify studies that may have been indexed under regional names. For countries with non-English as well as English names, both names will be used during searching while countries that have changed names during the period 2000-2016 will have all the names included in the search. Medical Subject Headings (MeSH) terms will be used when searching for studies in MEDLINE and PubMed. Endnote 7 will be used to manage retrieval of articles and screening for duplicates.
Procedure for selection of studies Articles retrieved from the search will be exported to Endnote X7 where duplicates will be identified. Two investigators will screen titles, abstracts and if necessary full articles for inclusion. The full articles will then be screened for eligibility independently by the two investigators. If the investigators do not agree, a third investigator will be consulted. Trained interpreters will translate articles in languages other than English and French into English.
Assessment of the quality of and risk of bias in included studies Two investigators will independently assess the included articles for the risk of bias and quality. They will resolve any differences by discussion and a third investigator will be consulted if they fail to reach consensus. Included studies will be assessed for quality (internal and external validity as well as risk of bias) using the validated quality appraisal tool developed by Hoy et al.
24
Data extraction and management After the studies have been assessed for risk of bias, two authors will independently extract data from the selected articles into a predefined data extraction form in Microsoft Office Excel 2016, which will first be piloted using five studies. The two investigators will compare their findings and discuss to resolve any differences. Data to be extracted from the articles will include author names, date of publication, country where study was conducted, number of participants included and proportion of participants who were women of childbearing age, main findings, study design, language, sampling method, response rate, risk factors for T2DM and unadjusted T2DM prevalence estimates which will be extracted as the number of cases (denominator) out of the number in each age group (numerator).
We will use a predefined data extraction form in Microsoft Office Excel 2016, which will first be piloted using five studies.
We will contact authors to get information on agespecific prevalence should it not be reported.
Data synthesis and analysis
For data that we are unable to conduct a meta-analysis, we will provide a narrative description. These data will include study characteristics such as year of publication, sample size and country where study and attributes associated with T2DM in women of childbearing age.
We will recalculate unadjusted estimates of the prevalence of T2DM and IGR among women within the age groups of (15-49) years (number of cases/sample size) together with SEs based on the information on crude numerators and denominators provided in the individual studies. We will pool the T2DM prevalence using the statistical software R V.3. Should included studies not have age-specific prevalence of T2DM we will write to the authors and request the data.
We will assess heterogeneity between studies using Cochran's Q statistic. 25 The Q-statistic tests for heterogeneity based on the null hypothesis that all studies share a common effect size. We will do the hypothesis testing based on a 0.10 level of significance, that is a p value of <0.10, implying that studies do not share a common effect size. To estimate the percentage of total variation across studies due to true between-study differences rather than chance, we will use the I 2 statistic (<25% as low, between 25% and 50% as moderate and >75% high heterogeneity). 25 26 Sources of heterogeneity will be explored through subgroup analysis using study-level characteristics such as geographical regions, rural/urban settings, age groups, study period, year of publication and sample sizes. This will be complemented where relevant, by meta-regression to further explain the heterogeneity, if any.
Assessment of publication bias
We will assess the presence of publication bias examining the funnel plots, supplemented with a formal statistical testing using the Egger test, 27 and the Begg's test 28 for publication bias. To test the robustness of our findings to publication bias, we will apply the Duval and Tweedie's trim and fill methods. 
